Human Anti-DR5 Recombinant Antibody (clone Apomab) (CAT#: PABL-453)

Figure 1 ELISA analysis of Apomab binding to DR5.

Apomab binding to purified human IgG1 Fc fusion proteins based on the human Apo2L/TRAIL receptors DR5, DR4, DcR1, DcR2 and OPG (Genentech Inc.). Binding was determined in ELISA format: each receptor–Fc fusion was coated onto microtiter wells and incubated with a serial dilution of Apomab for 2 h at room temperature. Bound Apomab was then detected using a horseradish peroxidase-conjugated goat F(ab′)2 anti-human IgG antibody.

Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., ... & Compaan, D. (2008). Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell death and differentiation, 15(4), 751.

Figure 3 Anti-DR5 Antibody (PABL-453) in Dot Blot

Dot Blot analysis of PABL-453 was performed by coating with Recombinant Human DR5 Protein (his Tag).

PABL-453 incubation concentration: 1 ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)

Figure 1 Anti-DR5 Antibody (PABL-453) in ELISA

ELISA analysis of PABL-453 was performed by coating with Recombinant Human DR5 Protein (his Tag). Then blocked with BSA and incubated with Anti-Human DR5 Antibody (PABL-453). The HRP-conjugated goat anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 2 Anti-DR5 Antibody (PABL-453) in WB

Western blot analysis of PABL-453 was performed by loading Recombinant Human DR5 Protein (his Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABL-453 and HRP Goat Anti-Human IgG as a secondary antibody. Chemiluminescent detection was performed.